This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Malaria	PD-1 receptor (PDCD1; PD-1; CD279); programmed cell death 1 ligand 1 (CD274 molecule; PD-L1; B7-H1); lymphocyte-activation gene 3 (LAG3; CD223)	<p>Patient sample and mouse studies suggest inhibiting PD-L1 and LAG3 could help treat malaria. In mouse models of malaria infection, blocking LAG3 and the PD-1 ligand PD-L1 restored host T cell function and cleared infection compared with blocking each separately. Next steps could include testing the strategy in additional animal models.</p> <p>Immutep S.A.'s anti-LAG3 antibody ImmuTune IMP701 is in preclinical testing for cancer. Immutep and GlaxoSmithKline plc have the anti-LAG3 antibody ImmuTune IMP731 in preclinical testing for transplant.</p> <p>Bristol-Myers Squibb Co. has an anti-PD-1 antibody in Phase I testing to treat solid tumors.</p> <p>SciBX 5(1); doi:10.1038/scibx.2012.18 Published online Jan. 5, 2012</p>	Patent and licensing status unavailable	<p>Butler, N.S. <i>et al. Nat. Immunol.</i>; published online Dec. 11, 2011; doi:10.1038/ni.2180</p> <p>Contact: John T. Harty, The University of Iowa, Iowa City, Iowa e-mail: john-harty@uiowa.edu</p>